Bliss GVS Pharma Q2 Net Profit at ₹272.5 Million; Revenue Rises to ₹2.44 Billion on Export Strength

Bliss GVS Pharma Ltd has posted a resilient performance for the quarter ended September 2025, with revenue from operations climbing to ₹2.44 billion and net profit reaching ₹272.5 million. The company continues to benefit from its strategic focus on international markets, especially in Africa and Southeast Asia.

The quarter saw operating profit grow 25.5% QoQ, supported by cost optimization, supply chain efficiency, and product mix improvements. The company’s dermatology and anti-infective segments remained key growth drivers, while its contract manufacturing operations added incremental revenue.

Bliss GVS is also expanding its footprint in regulated markets, with new filings and partnerships underway. Management reaffirmed its commitment to R&D investment, compliance, and sustainable growth, with expectations of stronger performance in H2 FY2026.

Key Highlights:

Revenue from Operations: ₹2.44 billion

Net Profit: ₹272.5 million

Growth Drivers: Export demand, dermatology, anti-infectives

Operational Trends: 25.5% QoQ rise in operating profit

Strategic Focus: Regulated market expansion, R&D, compliance

Bliss GVS Pharma’s Q2 results reflect its agility and strategic clarity in navigating global pharmaceutical dynamics.

Sources: Bliss GVS Pharma Quarterly Reports, LiveMint, Moneycontrol